CNBC September 10, 2024
Good afternoon! A large swath of insured Americans could be eligible for a highly popular class of weight loss and diabetes medications called GLP-1s, such as Novo Nordisk‘s Wegovy and Ozempic.
At least two in five U.S. adults — or more than 57 million people – under the age of 65 with private insurance could be eligible for GLP-1s according to clinical criteria, a new analysis from health policy research organization KFF found. That includes over 36 million people with an obesity diagnosis alone.
GLP-1s are approved to treat adults with Type 2 diabetes or obesity, or who are overweight with at least one weight-related health condition, such as cardiovascular disease, hypertension or high cholesterol. Novo Nordisk’s weight loss...
Today's Sponsors
Today's Sponsor